NO963371D0 - Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det - Google Patents
Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av detInfo
- Publication number
- NO963371D0 NO963371D0 NO963371A NO963371A NO963371D0 NO 963371 D0 NO963371 D0 NO 963371D0 NO 963371 A NO963371 A NO 963371A NO 963371 A NO963371 A NO 963371A NO 963371 D0 NO963371 D0 NO 963371D0
- Authority
- NO
- Norway
- Prior art keywords
- hematopoiesis
- protein
- making
- materials
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19602594A | 1994-02-14 | 1994-02-14 | |
US20319794A | 1994-02-25 | 1994-02-25 | |
US21520394A | 1994-03-21 | 1994-03-21 | |
US25249194A | 1994-06-01 | 1994-06-01 | |
PCT/US1994/008806 WO1995021920A1 (en) | 1994-02-14 | 1994-08-05 | Hematopoietic protein and materials and methods for making it |
Publications (2)
Publication Number | Publication Date |
---|---|
NO963371D0 true NO963371D0 (no) | 1996-08-13 |
NO963371L NO963371L (no) | 1996-10-11 |
Family
ID=27498094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO963371A NO963371L (no) | 1994-02-14 | 1996-08-13 | Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det |
Country Status (17)
Country | Link |
---|---|
US (1) | US5989537A (no) |
EP (1) | EP0745125A1 (no) |
JP (1) | JPH09508797A (no) |
KR (1) | KR100289201B1 (no) |
CN (1) | CN1148408A (no) |
AU (1) | AU691828B2 (no) |
BG (1) | BG63508B1 (no) |
BR (1) | BR9408534A (no) |
CA (1) | CA2183266A1 (no) |
CZ (1) | CZ221496A3 (no) |
FI (1) | FI963185A (no) |
HU (1) | HUT75359A (no) |
NO (1) | NO963371L (no) |
NZ (1) | NZ271230A (no) |
PL (1) | PL178384B1 (no) |
SK (1) | SK100896A3 (no) |
WO (1) | WO1995021920A1 (no) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO115788B1 (ro) * | 1994-03-31 | 2000-06-30 | Amgen Inc. | Polipeptidă mgdf, derivat de polipeptidă mgdf, polipeptidă mgdf mono-pegilată şi procedee de obţinere a acestora |
US5795569A (en) * | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
TW387940B (en) * | 1995-01-17 | 2000-04-21 | Kirin Brewery | Anti-tpo monodonal antibody |
CA2212006A1 (en) | 1995-02-03 | 1996-08-08 | G.D. Searle & Co. | Novel c-mpl ligands |
US5696250A (en) * | 1995-02-15 | 1997-12-09 | Amgen Inc. | DNA encoding megakaryocyte growth and development factor analogs |
US5989538A (en) * | 1995-02-15 | 1999-11-23 | Amgen Inc. | Mpl ligand analogs |
TW434021B (en) * | 1995-03-15 | 2001-05-16 | Kirin Brewery | Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions |
TW434020B (en) * | 1995-03-15 | 2001-05-16 | Kirin Brewery | Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions |
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6251864B1 (en) | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
EP1961760A3 (en) | 1995-06-07 | 2008-09-03 | Glaxo Group Limited | Peptides and compounds that bind to a thrombopoietin receptor |
TW497972B (en) * | 1995-06-08 | 2002-08-11 | Kirin Brewery | Stable thrombopoietin (TPO)-containing lyophilized compositions |
US6060052A (en) * | 1995-10-30 | 2000-05-09 | Systemix, Inc. | Methods for use of Mpl ligands with primitive human hematopoietic stem cells |
US5792850A (en) * | 1996-05-23 | 1998-08-11 | Zymogenetics, Inc. | Hematopoietic cytokine receptor |
US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
US6884419B1 (en) * | 1996-12-23 | 2005-04-26 | Kyowa Hakko Kogyo, Co., Ltd. | hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same |
US20030228666A1 (en) | 1998-06-30 | 2003-12-11 | Daewoong Pharmaceutical Co., Ltd. | Novel human thrombopoietin mutein |
MEP42108A (en) | 1998-10-23 | 2011-02-10 | Kiren Amgen Inc | Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
JP4739526B2 (ja) | 1998-12-07 | 2011-08-03 | ザイモジェネティクス, インコーポレイテッド | 成長因子相同体zvegf3 |
US6776984B1 (en) | 1999-08-20 | 2004-08-17 | George R. Schwartz | Induced regeneration and repair of damaged neurons and nerve axon myelin |
CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
EP1294888B1 (en) | 2000-06-30 | 2007-04-25 | ZymoGenetics, Inc. | Interferon-like protein zcyto21 |
US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
EP1336846A1 (en) * | 2002-02-13 | 2003-08-20 | Procorde GmbH | Method for generating recombinant human platelets for identifying therapeutic target proteins |
WO2003080806A2 (en) * | 2002-03-18 | 2003-10-02 | National Jewish Medical And Research Center | Method for production of neutrophils and uses therefor |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
DE10227611A1 (de) * | 2002-06-20 | 2004-01-15 | Bionethos Holding Gmbh | Verfahren und Vorrichtung zur Vermehrung und Differenzierung von Zellen in Anwesenheit von Wachstumsfaktoren und einer biologischen Matrix oder Trägerstruktur |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
WO2004014938A2 (en) * | 2002-08-09 | 2004-02-19 | Xencor | Thrombopoiesis-stimulating proteins having reduced immunogenicity |
PT1542714E (pt) | 2002-09-18 | 2014-06-23 | Janssen Pharmaceuticals Inc | Métodos para aumentar a produção de células estaminais plaquetárias e hematopoiéticas |
US20090143453A1 (en) * | 2003-04-29 | 2009-06-04 | Connie Erickson-Miller | Methods for treating degenerative diseases/injuries |
US20100004302A1 (en) * | 2003-04-29 | 2010-01-07 | Connie Erickson-Miller | Methods for Treating Degenerative Diseases/Injuries |
US20090048318A1 (en) * | 2003-04-29 | 2009-02-19 | Connie Erickson-Miller | Methods for treating degenerative diseases/injuries |
WO2004096154A2 (en) | 2003-04-29 | 2004-11-11 | Smithkline Beecham Corporation | Methods for treating degenerative diseases/injuries |
US20090298179A1 (en) * | 2003-04-29 | 2009-12-03 | Connie Erickson-Miller | Methods For Treating Degenerative Diseases/Injuries |
ATE388963T1 (de) | 2003-08-07 | 2008-03-15 | Zymogenetics Inc | Homogene herstellungen von il-29 |
US7723295B2 (en) | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
PL1675606T3 (pl) | 2003-08-28 | 2017-08-31 | Janssen Pharmaceuticals, Inc. | Peptydy i związki, które wiążą się z receptorami trombopoetyny |
EP1682074B1 (en) * | 2003-10-24 | 2012-02-08 | Nora Therapeutics, Inc. | Compositions and methods for healthy pregnancy |
US20090226397A1 (en) * | 2003-10-24 | 2009-09-10 | Nora Therapeutics, Inc. | Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
US8338373B2 (en) * | 2003-10-24 | 2012-12-25 | Nora Therapeutics, Inc. | Method for reducing the risk of spontaneous abortion in a human female subject |
PL1699915T3 (pl) | 2003-12-30 | 2010-11-30 | Augustinus Bader | Zastosowanie erytropoetyny do regeneracji tkanki wątrobowej |
EP1773400A2 (en) | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutic peptides |
CA2585343C (en) | 2004-10-25 | 2016-06-21 | Cellerant Therapeutics, Inc. | Methods of expanding myeloid cell populations and uses thereof |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
WO2007102946A2 (en) | 2006-01-23 | 2007-09-13 | Amgen Inc. | Crystalline polypeptides |
US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
KR101040396B1 (ko) | 2009-01-20 | 2011-06-09 | 한올바이오파마주식회사 | 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5154921A (en) * | 1990-07-13 | 1992-10-13 | Dana-Farber Cancer Institute, Inc. | Promotion of maturation of hematopoietic progenitor cells |
US5571686A (en) * | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
-
1994
- 1994-08-05 CA CA002183266A patent/CA2183266A1/en not_active Abandoned
- 1994-08-05 AU AU74810/94A patent/AU691828B2/en not_active Ceased
- 1994-08-05 WO PCT/US1994/008806 patent/WO1995021920A1/en not_active Application Discontinuation
- 1994-08-05 BR BR9408534A patent/BR9408534A/pt not_active Application Discontinuation
- 1994-08-05 HU HU9602224A patent/HUT75359A/hu unknown
- 1994-08-05 JP JP7521187A patent/JPH09508797A/ja active Pending
- 1994-08-05 EP EP94924579A patent/EP0745125A1/en not_active Withdrawn
- 1994-08-05 KR KR1019960704354A patent/KR100289201B1/ko not_active IP Right Cessation
- 1994-08-05 PL PL94315914A patent/PL178384B1/pl unknown
- 1994-08-05 SK SK1008-96A patent/SK100896A3/sk unknown
- 1994-08-05 NZ NZ271230A patent/NZ271230A/en unknown
- 1994-08-05 CN CN94194997A patent/CN1148408A/zh active Pending
- 1994-08-05 CZ CZ962214A patent/CZ221496A3/cs unknown
-
1995
- 1995-06-07 US US08/484,257 patent/US5989537A/en not_active Expired - Lifetime
-
1996
- 1996-08-06 BG BG100771A patent/BG63508B1/bg unknown
- 1996-08-13 NO NO963371A patent/NO963371L/no not_active Application Discontinuation
- 1996-08-14 FI FI963185A patent/FI963185A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
PL315914A1 (en) | 1996-12-09 |
CN1148408A (zh) | 1997-04-23 |
KR100289201B1 (ko) | 2001-05-02 |
US5989537A (en) | 1999-11-23 |
HU9602224D0 (en) | 1996-10-28 |
AU7481094A (en) | 1995-08-29 |
PL178384B1 (pl) | 2000-04-28 |
SK100896A3 (en) | 1997-10-08 |
FI963185A0 (fi) | 1996-08-14 |
BG63508B1 (bg) | 2002-03-29 |
JPH09508797A (ja) | 1997-09-09 |
AU691828B2 (en) | 1998-05-28 |
BG100771A (en) | 1997-08-29 |
CA2183266A1 (en) | 1995-08-17 |
NO963371L (no) | 1996-10-11 |
FI963185A (fi) | 1996-08-14 |
WO1995021920A1 (en) | 1995-08-17 |
HUT75359A (en) | 1997-05-28 |
BR9408534A (pt) | 1997-08-05 |
CZ221496A3 (en) | 1997-07-16 |
NZ271230A (en) | 1998-03-25 |
EP0745125A1 (en) | 1996-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO963371D0 (no) | Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det | |
IS1810B (is) | Úðablöndur úr peptíðum og próteinum | |
NO20071415L (no) | OB-fusjonsproteinpreparater og fremgangsmater | |
NO20000700D0 (no) | Interleukin-18-proteiner samt fremstilling og anvendelse derav | |
DE69616813D1 (de) | Halographisches aufzeichnungsmaterial und verfahren | |
FI935485A (fi) | PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset | |
BR9407089A (pt) | Moega e método | |
BR9506832A (pt) | N-pirazolilanilinas e n-pirazolilaminopiridinas | |
DE69527170T2 (de) | Navigationsvorrichtung und -verfahren | |
KR960008810A (ko) | 편집 방법 및 편집 제어 기기 | |
DE69528180D1 (de) | Modifiziertes molkeprotein | |
DK132892D0 (da) | Proteiner | |
DE69409379D1 (de) | Ultraschallabtastgerät und -verfahren | |
NO971505D0 (no) | Trofinin og trofininhjelperproteiner | |
FI972763A0 (fi) | Mutanttiproteiineja | |
DE69425770D1 (de) | Direktes Aufzeichnungsverfahren und direkte Aufzeichnungsvorrichtung | |
NO960766D0 (no) | Nytt protein og fremgangsmåte for fremstilling av dette | |
TR199701666A3 (tr) | Sismanliga karsi proteinler | |
KR960010685A (ko) | 펩티드 및 그 용도 | |
DE69614491T2 (de) | 5HT1Dalpha und 5HT2A Ligande | |
BR9507133A (pt) | N-aril e n-alquilsulfonilaminais | |
DK120792D0 (da) | Protein | |
SE9602287D0 (sv) | Novel protein and methods for its use | |
KR960005550U (ko) | 볼트 | |
DE69519715D1 (de) | PRLTS-Proteine und die dafür kodierende DNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |